Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.36 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.33 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.33 |
| ▸ | GSR | P00390 | 2/20 | 0.32 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.32 |
| ▸ | BTN3A1 | O00481 | 1/20 | 0.31 |
| ▸ | GBA1 | P04062 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28442052 | 0.83 | NFE2L2 (0.34) | NFE2L2 | |
| SCHEMBL28443027 | 0.83 | NFE2L2 (0.34) | NFE2L2 | |
| SCHEMBL28442054 | 0.83 | NFE2L2 (0.34) | NFE2L2 | |
| SCHEMBL9396039 | 0.82 | NFE2L2 (0.36) | NFE2L2CHRM2CHRM1BTN3A1GBA1 | |
| SCHEMBL9398186 | 0.80 | NPC1 (0.36) | NFE2L2CHRM2CHRM1BTN3A1GBA1 | |
| SCHEMBL28446707 | 0.79 | NFE2L2 (0.34) | NFE2L2 | |
| SCHEMBL28441485 | 0.79 | NFE2L2 (0.34) | NFE2L2 | |
| SCHEMBL31695288 | 0.72 | ATM (0.39) | NFE2L2 | |
| SCHEMBL12306794 | 0.72 | MEN1 (0.37) | NFE2L2CHRM2CHRM1 | |
| SCHEMBL3225736 | 0.71 | CHRM2 (0.50) | CHRM2CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100022461-A1 | Novel Derivatives of Cyclic Compound And The Use Thereof | WONKISOPHARM CO., LTD. (KR) | 2010-01-28 | — | — | US | claimed |
| WO-2008004788-A1 | NOVEL DERIVATIVES OF CYCLIC COMPOUND AND THE USE THEREOF | WONKISOPHARM CO., LTD. (KR) | 2008-01-10 | — | — | WO | claimed |
| US-8420853-B2 | Derivatives of cyclic compound and the use thereof | Wonkisopharm Co., Ltd (KR) | 2013-04-16 | — | — | US | disclosed |
| US-20100022461-A1 | Novel Derivatives of Cyclic Compound And The Use Thereof | WONKISOPHARM CO., LTD. (KR) | 2010-01-28 | — | — | US | disclosed |
| WO-2008004788-A1 | NOVEL DERIVATIVES OF CYCLIC COMPOUND AND THE USE THEREOF | WONKISOPHARM CO., LTD. (KR) | 2008-01-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100022461-A1 | Novel Derivatives of Cyclic Compound And The Use Thereof | TYR, MC1R, PDE7A | NFE2L2 93/4885CHRM2 4272/4885CHRM1 4444/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.